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Non-cystic fibrosis (CF) bronchiectasis is characterised by chronic airway infection and neu-
trophilic inflammation, which we hypothesised would be associated with Th17 pathway
activation.
Methods
Th17 pathway cytokines were quantified in bronchoalveolar lavage fluid (BALF), and gene
expression of IL-17A, IL-1β, IL-8 and IL-23 determined from endobronchial biopsies (EBx)
in 41 stable bronchiectasis subjects and 20 healthy controls. Relationships between IL-17A
levels and infection status, important clinical measures and subsequent Pseudomonas aer-
uginosa infection were determined.
Results
BALF levels of all Th17 cytokines (median (IQR) pg/mL) were significantly higher in bronchi-
ectasis than control subjects, including IL-17A (1.73 (1.19, 3.23) vs. 0.27 (0.24, 0.35), 95%
CI 1.05 to 2.21, p<0.0001) and IL-23 (9.48 (4.79, 15.75) vs. 0.70 (0.43, 1.79), 95% CI 4.68
to 11.21, p<0.0001). However, BALF IL-17A levels were not associated with clinical mea-
sures or airway microbiology, nor predictive of subsequent P. aeruginosa infection. Further-
more, gene expression of IL-17A in bronchiectasis EBx did not differ from control. In
contrast, gene expression (relative to medians of controls) in bronchiectasis EBx was signif-
icantly higher than control for IL1β (4.12 (1.24, 8.05) vs 1 (0.13, 2.95), 95% CI 0.05 to 4.07,
p = 0.04) and IL-8 (3.75 (1.64, 11.27) vs 1 (0.54, 3.89), 95% CI 0.32 to 4.87, p = 0.02) and
BALF IL-8 and IL-1α levels showed significant relationships with clinical measures and
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airway microbiology. P. aeruginosa infection was associated with increased levels of IL-8
while Haemophilus influenzae was associated with increased IL-1α.
Conclusions and Clinical Relevance
Established adult non-CF bronchiectasis is characterised by luminal Th17 pathway activa-
tion, however this pathway may be relatively less important than activation of non-antigen-
specific innate neutrophilic immunity.
Introduction
Bronchiectasis is a condition characterised by permanent bronchial dilatation which can result
from a myriad of underlying aetiologies, although most cases are idiopathic [1]. The prevalence
of non-CF bronchiectasis (hereafter bronchiectasis) is poorly characterised, however it is fre-
quently encountered in clinical practice and emerging evidence suggests a greater prevalence
than previously appreciated [2]. Additionally, bronchiectasis is a common respiratory co-pa-
thology, present in at least 30% of those with smoking-related chronic obstructive pulmonary
disease (COPD) [3]. Furthermore, recent data suggest that the co-existence of bronchiectasis in
COPD subjects is independently associated with a more than doubling in the risk of death [4].
Airway inflammation in bronchiectasis is characterised by neutrophil-dominated inflam-
mation associated with elevated levels of proinflammatory cytokines and chemokines such as
IL-8, IL-6 and TNF-α in bronchoalveolar lavage fluid (BALF)[5]. Furthermore, significant rela-
tionships have been shown to exist between airway inflammation and microbiology assessed
by both culture and molecular methods [5–7], supporting Cole’s proposed ‘vicious cycle’ hy-
pothesis [8]. Neutrophil-predominant acute inflammation is typical of the inflammatory re-
sponse associated with the antigen-specific Th17 T cell pathway, whose primary function
appears to be clearance of extracellular bacterial and fungal pathogens, and hence this pathway
is likely to be involved in bronchiectasis [9]. The major product of Th17 cells, IL-17A, stimu-
lates local cytokine (eg IL-1β, TNF-α and IL-6) and chemokine (eg CXCL1, CXCL2, CXCL5
and CXCL8/IL-8) secretion by other cells, inducing neutrophil recruitment and activation [9].
Additionally, IL-17 induces the release of matrix metalloproteinases (MMPs) from various cell
types, resulting in matrix destruction [9]. MMP’s have been shown to be elevated in bronchiec-
tasis and may be important in the processes leading to bronchiectasis itself [10].
Recent studies have demonstrated elevated levels of IL-17A in BALF from children with CF
[11,12]. In CF children, elevated BALF IL-17A levels at baseline were associated with subse-
quent acquisition of Pseudomonas aeruginosa infection [12], and increases in cells staining pos-
itive for IL-17 have been identified in airway mucosal biopsies from both CF and non-CF
bronchiectasis children [11]. The potential involvement of this pathway in adults with estab-
lished bronchiectasis remains incompletely defined, limited to a single study in which IL-17
was detected in exhaled breath condensate [13].
As part of the Bronchiectasis and Low-dose Erythromycin Study (BLESS) [14], we evaluated
the Th17 pathway in a subgroup of subjects who underwent bronchoscopy at baseline. We hy-
pothesized that subjects with non-CF bronchiectasis would demonstrate significant activation
of the Th17 pathway. Furthermore, we sought to evaluate potential associations between base-
line BALF IL-17A and airway infection by pathogens, particularly P. aeruginosa, and the devel-
opment of new P. aeruginosa infection in the 12 months following sampling.
Th17 Pathway Activation in Non-CF Bronchiectasis
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Methods
Subjects and procedures (further details in S1 Supporting Information for
all sections)
This study was approved by the Mater Health Services Human Research Ethics Committee
(1244A) and all subjects provided written, informed consent. All sample processing and evalu-
ation was undertaken with complete blinding to disease state and study treatment assignment.
A subgroup of 41 participants randomised in the BLESS study [14] underwent bronchoscopic
sampling at baseline, prior to commencing assigned trial medication. Subjects in this subgroup
had no evidence of additional (non-bronchiectasis) chronic respiratory disease. The normal
control group comprised 20 healthy volunteers recruited from hospital and research institute
staff. All bronchoscopies were performed by the same proceduralist (DJS). All control and
bronchiectasis subjects were macrolide-naïve, lifelong non-smokers (<2 pack year history),
aged 18–85 years, with no history of asthma or atopy, recent respiratory tract infection (within
4 weeks) or conditions with the potential to impact the safe performance of bronchoscopy.
(Full study details including inclusion and exclusion criteria are provided in S1 Supporting
Information).
Bronchoscopy was performed as an outpatient procedure under conscious sedation. After
the application of lignocaine to the airways, BAL was first performed in the right middle lobe
and then endobronchial biopsies collected from subsegmental carinae of the lower lobes. BAL
fluid (BALF) samples were placed on ice and processed immediately following the procedure.
At screening, control and bronchiectasis subjects had demographic data collected and com-
pleted spirometry before and after inhalation of salbutamol bronchodilator. Bronchiectasis
subjects provided a 24 hour sputum sample, completed symptom (Leicester Cough/ LCQ) and
quality of life (QOL; St George’s Respiratory/ SGRQ) questionnaires, produced a sputum sam-
ple for microbiology and completed a 6-minute walk test (6MWT) [14]. (Further details are
provided in S1 Supporting Information).
Gene expression from endobronchial biopsies
Two endobronchial biopsies for RNA extraction were placed into a tube containing 0.5 mL of
RNA Later solution (Life Technologies, Carlsbad, CA) and stored at -80°C for subsequent pro-
cessing. RNA was extracted from biopsies and amplified (Ovation Amplification Kit, NuGen,
San Carlos, CA) prior to analysis of gene expression of IL-1β, IL-8, IL-17A and IL-23 by Taq-
Man qRT-PCR (Microfluidic Cards, Life Technologies, Carlsbad, CA) as per the manufactur-
er’s instructions. All qRT-PCR results were corrected for a group of three house-keeping genes.
BALF processing
The BALF sample was separated into 1 mL aliquots and immediately placed on ice. One sample
was sent to the microbiology laboratory, a second sample was processed within 30 minutes for
differential cell counts, and a third processed within 60 minutes to generate supernatant for
cytokine analysis.
Cytokine and chemokine analysis
The Procarta Luminex cytokine and chemokine array (Affymetrix, Santa Clara, CA) was used
to determine concentrations of IL-1α, IL-1β, IL-6, IL-8, IL-17A, IL-23 and TNF- α in 50 μL
concentrated (by 10kDa cut-off centrifugal concentrator) BALF supernatant with protease in-
hibitor. Reported results have been converted back to original concentrations per mL of BALF.
Th17 Pathway Activation in Non-CF Bronchiectasis
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Data analysis
Sample size calculations for the BLESS study are as described previously [14,15]. Data distribu-
tion was mostly non-parametric and Mann-Whitney U tests were used to test the significance
of variance between control and disease groups, or Kruskal-Wallis test where 3 or more groups
were compared (with post-hoc Mann-Whitney U test). Correlations were calculated using
Spearman rank correlation coefficient. All analyses were 2-sided and p values<0.05 were con-
sidered significant. Statistical analyses were performed using StatsDirect statistical software
(version 2.7.8, Cheshire, United Kingdom).
Results
Demographic details are shown in Table 1. BALF was available for all subjects and EBx for all
control and 34 bronchiectasis subjects. Given significant differences between disease and con-
trol groups for age and use of ICS (either as monotherapy or as ICS/ LABA combination inhal-
ers), multivariate regression analysis was undertaken (incorporating presence/ absence of
bronchiectasis, ICS use, age, FEV1 as a percentage of the predicted value and gender) which
showed no relationship between either of these variables and BALF IL-17A levels. The only
significant independent predictor in this model was the presence of bronchiectasis (r = 0.3,
p = 0.03).
BALF
Median (IQR) levels of IL-17A were highly significantly increased in non-CF bronchiectasis
(1.73 (1.19, 3.23) compared with control BALF (0.27 (0.24, 0.35) pg/mL, median difference
1.45, 95% CI 1.05 to 2.21, p<0.0001, Fig 1A). There were no significant differences in IL-17A
levels within bronchiectasis subjects according to concurrent BALF culture results (P. aerugi-
nosa (n = 9), 2.20 (1.39, 3.26), Haemophilus influenzae (n = 11) 1.46 (1.17, 2.46), normal respi-
ratory flora only (n = 14) 1.85 (0.43, 4.42), p = 0.49 by K-W). Surprisingly, there were no
differences in IL-17A levels between subjects with positive BALF bacterial culture (n = 27)
(1.73 (1.26, 3.23)) and those with negative cultures (n = 14)(1.85 (0.43, 4.42), p = 0.68). Levels
of IL-17A from bronchiectasis patients with chronic P. aeruginosa infection (2.58 (1.56, 3.34)
n = 8) did not differ significantly from those with intermittent (1.90) (1.17, 3.94) n = 7) or no
P. aeruginosa infection (2.14 (0.92, 2.68) n = 26, p = 0.26 by K-W). Finally, in contrast to the re-
cent publication in CF children [12], bronchiectasis adults without chronic P. aeruginosa infec-
tion at baseline who subsequently cultured P. aeruginosa within 12 months did not have
significantly higher levels of IL-17A (n = 10) (2.33 (1.11, 4.66) than those who did not (n = 23)
(1.51 (1.17, 2.46), 95% CI for median difference -2.69 to 0.8, p = 0.64).
Furthermore, IL-17A levels in BALF did not correlate with baseline percent-predicted
FEV1, SGRQ, LCS and did not differ significantly between those with a 12 month history
of 5 exacerbations versus those with<5. BALF IL-17A levels correlated significantly but
weakly with BALF neutrophils (r = 0.35, p = 0.04), and strongly with all measured Th17 path-
way cytokines (r>0.83 for all except IL-1α 0.68) with the strongest correlations to IL-23 (r
0.91, p<0.0001, Fig 2), TNF-α (r 0.90, p<0.0001) and IL-6 (r = 0.85, p<0.0001).
Compared to normal controls, subjects with non-CF bronchiectasis also had highly signifi-
cantly elevated BALF levels of all measured Th17 pathway cytokines (IL-1α, IL1β, IL-6, IL-8,
IL-23 and TNF-α (p<0.0001 for all, Fig 2).
Of these other cytokines and chemokines, only IL-8 and IL-1α showed differences according
to BALF microbiology. IL-8 levels were significantly higher in those with positive (n = 27)
(44.04 (14.66, 78.77) than negative BALF bacterial cultures (n = 14) (9.47 (2.38, 37.89), 95% CI
1.88–51.38, p = 0.03). Levels of IL-8 were also significantly elevated in those with P. aeruginosa
Th17 Pathway Activation in Non-CF Bronchiectasis
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Table 1. Subject demographics and disease characteristics.
Control (n = 20) Non-CF Bronchiectasis (n = 41)
Age (years) 36 (±11.8) 63 (±6.9)
Female—No. (%) 12 (60) 28 (68)
FEV1 (L)—pre-bronchodilator 3.52 (±0.83) 1.87 (±0.61)
FEV1 (L)—post-bronchodilator 3.61 (±0.83) 1.97 (±0.64)
FEV1% predicted (pre-bronchodilator) 97.9 (±12.6) 72.9 (±15.30)
FEV1% predicted (post-bronchodilator) 100.4 (±11.70) 76.8 (±14.42)
Pseudomonas aeruginosa in sputum—No. (%) - 11 (27)
Other sputum pathogens—No. (%)
Normal ﬂora only (no pathogens) - 17 (41)
Haemophilus inﬂuenzae - 12 (29)
Stenotrophomonas maltophilia - 1 (2)
Others - 3 (7)
5 exacerbations in the prior year—No. (%) - 16 (39)
24 hour sputum weight (g)—median (95% CI) - 16.4 (13 to 20)
St George’s Respiratory Questionnaire* - 39.4 (±14.4)
Leicester cough questionnaire* (LCS) - 14.2 (±4)
6MWT (m)—median (95% CI) - 510 (480 to 540)
Differential cell counts ** - median (IQR)
Total cell count (X 106/ mL) - 52.1 (31.2, 76.9)
Macrophages (X 106/ mL) - 25.2 (1.1, 52.8)
Macrophage % - 42.6 (3.8, 75)
Neutrophil (X 106/ mL) - 9.3 (3.4, 39.6)
Neutrophil % - 39.3 (6, 90.2)
Lymphocytes (X 106/ mL) - 2.9 (0.5, 8.8)
Lymphocytes % - 6.8 (2.6, 14.9)
Medications—No.
Inhaled corticosteroids 0 5
Combination inhalers (ICS/LABA) 0 17
Inhaled LABA 0 2
Inhaled SABA 0 17
Inhaled anticholinergics 0 4
Prednisolone 0 0
Nebulised saline 0 2
Bromhexine 0 2
Comorbidities -
Ischaemic heart disease 0 2
Cerebrovascular disease 0 1
Hypertension 0 9
Diabetes mellitus 0 1
(Values are mean (±SD) unless otherwise indicated;
*lower scores on the LCS indicate worse cough symptoms, while lower scores on the SGRQ indicate better quality of life;
** Differential cell counts were performed on bronchiectasis BALF, and results exclude squamous and bronchial epithelial cells;
FEV1—forced expiratory volume in the ﬁrst second; 6MWT—6 minute walk test; ICS—inhaled corticosteroids; LABA—long-acting β-agonist, SABA—
short-acting β-agonist.)
doi:10.1371/journal.pone.0119325.t001
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in concurrent BALF (n = 9) (64.96 (46.4, 77.9) compared to those without P. aeruginosa
(n = 32) (15.23 (5.77, 59.81), 95% CI 8.54 to 59.11, p = 0.019), those with normal respiratory
flora cultured only (n = 14) (9.47 (2.38, 37.89), p = 0.016) and those withH. influenzae (n = 11)
(34.85 (6.84, 57.75), 95% CI 2.4 to 59.9, p = 0.047, Fig 3). Interestingly, levels of IL-1α were nu-
merically lower in those with BALF P. aeruginosa (n = 9) (20.25 (16.76, 28) thanH. influenzae
(n = 11) (32.18 (26.6, 70.18), however this trend was not statistically significant.
Exploratory analyses for IL-8 and IL-1α
Given these IL-8 and IL-1α findings according to BAL microbiology, and although not part of
our original intended evaluation, we undertook further evaluations of relationships between
Fig 1. Airway luminal but not mucosal levels of IL-17A are significantly increased in adult non-CF bronchiectasis compared with healthy control
subjects. (A) Bronchoalveolar lavage fluid levels of IL-17A comparing bronchiectasis (n = 41) and healthy control (n = 20) subjects; (B) Gene expression of
IL-17A in endobronchial biopsies from bronchiectasis (n = 34) and healthy control (n = 20) subjects. (Cont—control, BE—bronchiectasis; Box and whisker
plots display median and interquartile ranges; p values are by Mann-Whitney U test).
doi:10.1371/journal.pone.0119325.g001
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these 2 cytokines according to concurrent sputum microbiological results. Chronic pulmonary
infection was defined as all sputum cultures being positive for the stated organism in the 6
months prior to enrolment, including each culture from sputum and BALF samples collected at
screening and visit 1 for the BLESS study, and was hierarchical (P. aeruginosa>H. influenzae>
others>normal flora only). Intermittent infection was defined where the organism was not
cultured in every such specimen. ‘Baseline’ infection status was defined as per the BLESS study
[14]—subjects with P. aeruginosa cultured at either the screening or visit 1 sputum sample
were classified baseline P. aeruginosa positive, similarly for H. influenzae (if no P. aeruginosa
Fig 2. Bronchoalveolar lavage fluid levels of Th17 pathway cytokines and chemokines are significantly increased in adult non-CF bronchiectasis.
(A) All Th17 pathway mediators are significantly increased in non-CF bronchiectasis (n = 41) compared with healthy control (n = 20) subjects. (B)
Bronchoalveolar lavage fluid levels of IL-17A correlate strongly with all Th17 pathway mediators, but most strongly with IL-23 (n = 61). (Cont—control, BE—
bronchiectasis; Box and whisker plots display median and interquartile ranges; p values are by Mann-Whitney U test).
doi:10.1371/journal.pone.0119325.g002
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cultured) and if no pathogens cultured in either then baseline ‘normal flora’. These investiga-
tions raise the possibility of a divergence of inflammatory stimulation according to specific mi-
crobiology. BALF IL-8 levels in subjects with chronic pulmonary infection by P. aeruginosa
(n = 8) (63.08 (38.45, 73.4) did not differ from those with intermittent P. aeruginosa (n = 7)
(46.43 (12.78, 92.22), but were significantly higher than levels in subjects without sputum P.
aeruginosa (n = 26) (45.40 (3.44, 57.75), 95% CI 3.64 to 59.81, p = 0.043). IL-8 levels were sig-
nificantly higher in subjects who cultured P. aeruginosa at any time during the 12 month study
(n = 20)(53.82 (30.33,82.18) than those who did not (n = 21) (43.82 (3.44, 40.05), 95% CI 2.76
to 52.18, p = 0.03), however levels did not predict subsequent P. aeruginosa infection in sub-
jects without chronic P. aeruginosa at baseline (subsequent P. aeruginosa (n = 10) 54.15 (6.84,
92.22) vs no subsequent P. aeruginosa (n = 23) 12.78 (3.44, 44.04), p = 0.21).
IL-1α levels were significantly higher in subjects withH. influenzae (n = 11) (35.86 (29.2,
79.3) than subjects with P. aeruginosa (n = 12) (19.87 (15.7, 31.55), 95% CI 2.98 to 46.9,
p = 0.019) at baseline and in subjects with chronic H. influenzae infection (n = 8) (31.58 (29.21,
38.03) compared with chronic P. aeruginosa (n = 9) (19.87 (16.95, 27.88), 95% CI 1.21 to 42.05,
p = 0.036).
Fig 3. Airway luminal and bronchial mucosal levels of IL-8 are increased in non-CF bronchiectasis and relate to airwaymicrobiology. (A)
Bronchoalveolar lavage IL-8 levels are significantly increased in bronchiectasis subjects according to concurrent BALF infection by P. aeruginosa (n = 9)
compared to H. influenzae (n = 11), normal respiratory flora only (n = 14) and healthy controls (n = 20). (B) Gene expression of IL-8 is significantly increased
in endobronchial biopsy tissue from adult non-CF bronchiectasis (n = 34) than control (n = 20) subjects. (Cont—control, BE—bronchiectasis; Box and
whisker plots display median and interquartile ranges; p values by Mann-Whitney U test).
doi:10.1371/journal.pone.0119325.g003
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BALF IL-8 levels were significantly correlated with BALF neutrophil counts (r = 0.67,
p<0.0001), SGRQ symptoms scores (r = -0.48, p = 0.002) and LCS (r = 0.4, p = 0.01). BALF IL-
1α levels were significantly correlated with SGRQ total scores (r = -0.33, p = 0.03), SGRQ
symptoms (r = -0.38, p = 0.015) and LCS (r = 0.37, p = 0.017). Neither cytokine showed signifi-
cant correlations with FEV1 or exacerbation frequency.
Endobronchial biopsies
Gene expression of IL-17A in endobronchial biopsies did not differ between bronchiectasis
and normal control subjects (median difference 0.03, 95% CI -0.66 to 0.77, p = 0.95, see Fig 1).
However bronchiectasis subjects had significantly higher gene expression relative to the medi-
an of healthy controls for IL1β (4.12 (1.24, 8.05) vs 1 (0.13, 2.95), 95% CI 0.05 to 4.07, p = 0.04)
and IL-8 (3.75 (1.64, 11.27) vs 1 (0.54, 3.89), 95% CI 0.32 to 4.87, p = 0.02, Fig 3).
Discussion
The current study confirms, for the first time, significant airway luminal activation of the Th17
pathway in established adult non-CF bronchiectasis, in particular demonstrating significant el-
evations of BALF IL-17A and IL-23. However, in contrast to the recent publication in children
with non-CF bronchiectasis, adults with established disease did not demonstrate significantly
increased expression of IL-17A in endobronchial biopsies (assessed by gene expression rather
than immunohistochemistry) [11]. Additionally, in contrast to data in CF children, BALF IL-
17A levels did not predict subsequent P. aeruginosa infection [12]. Furthermore, we did not ob-
serve significant relationships between IL-17A levels and concurrent airway microbiology.
Rather, our results showed increased IL-8 levels in association with P. aeruginosa infection and
increased IL-1α levels in those withH. influenzae infection, suggesting both greater importance
of these neutrophil-related mediators than IL-17A in established, chronic airway infection, and
the possibility of divergent inflammatory activation according to specific microbiology. Our
data support the proposal that innate, neutrophil-rich inflammation is a more important con-
tributor to airway mucosal inflammatory pathophysiology in established adult non-CF bron-
chiectasis than a specific Th17 pathway response.
It is possible that our failure to demonstrate a more important role for the Th17 pathway
represents relative underpowering; however, we were able to demonstrate the importance of
IL-8 and IL-1 with this sample. Furthermore, these data are cross-sectional in nature and the
disease and control groups were not matched, with significant differences for both age and in-
haled corticosteroid use. However multivariate analyses did not identify any relationships be-
tween either of these variables and BALF IL-17A levels, with presence of bronchiectasis the
only variable that predicted IL-17a levels. Additionally, we sampled a relatively large patient
population for a study of this kind, and our bronchiectasis subjects, nested within our rigorous-
ly conducted, double-blind, randomised controlled BLESS study, were very well clinically char-
acterized. Other strengths of the study include the evidence of internal validity provided by the
strong relationships between all Th17 pathway cytokines.
Elevated levels of sputum IL-17A have previously been described in adult CF subjects
[16,17], although only one of those studies had a comparator control group [16]. In that study,
while sputum IL-17A gene expression was readily detected, the protein itself was unable to be
measured in any of the controls and 3 (of 16) CF subjects. Additionally, IL-17 levels in bronchi-
al mucosal tissue were not evaluated, and IL-23 was unable to be quantified at protein level
[16]. Difficulty in measuring IL-23 protein levels in respiratory secretions has been reported re-
cently [18,19]. Whether our ability to detect these cytokines in all healthy and bronchiectasis
subjects reflects differences in sample processing methods (eg our use of protease inhibition) is
Th17 Pathway Activation in Non-CF Bronchiectasis
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not clear. Nonetheless, the demonstration of significantly elevated BALF IL-23 protein levels
compared to controls is, to our knowledge, the first such data in human airways disease and
confirms involvement of this key Th17 cytokine in airway inflammation in adult non-CF bron-
chiectasis. Additionally, our finding that the cytokine most strongly correlated with IL-17 levels
was IL-23 is consistent with the ‘central role’ that IL-23 is believed to play in the Th17 pathway
and Th17 cell maturation within the lung [20].
Our findings extend those of prior studies establishing the importance of neutrophilic in-
flammation in adult bronchiectasis [5,6,21,22]. The most comprehensive BALF study in adult
non-CF bronchiectasis [5] demonstrated increased levels of neutrophil elastase, myeloperoxi-
dase, TNF-α, IL-6 and IL-8 but not IL1β compared to controls. In addition to revealing upregu-
lation of IL-1α, IL-17A and IL-23 and confirming increased BALF levels of IL-6, IL-8 and
TNF-α, our data also demonstrate highly significant increases in BALF IL-1β in contrast to
that earlier study. This difference may reflect the milder disease of subjects in that study, with
an average FEV1 79% predicted and a higher proportion of subjects negative for potential path-
ogens (52% vs 34% in our study).
The current data demonstrate highly significant increases in all Th17 pathway-associated
chemokines and cytokines measured in the airways of adult bronchiectasis subjects, including
pathway effectors (IL-17A, IL-6, IL-8 and TNF-α) and regulators (IL-1α, IL-1β, IL-6 and IL-
23). However, while gene expression of both IL-1β and IL-8 was significantly upregulated in
the bronchial mucosa of non-CF bronchiectasis subjects, IL-17A was not, possibly reflecting
the scarce relative abundance of the cells of origin in the mucosa. Interestingly, in spite of dem-
onstrating significant increases in the abundance of Th17 T cells in biopsies, Tan and col-
leagues did not demonstrate significant increases in BALF IL-17 in non-CF bronchiectasis
compared to control children [11]. Differences in findings between the 2 studies are likely to re-
flect differences in clinical status (our subjects were all clinically stable, versus all paediatric
bronchiectasis subjects being sampled at the time of exacerbation), age (young children vs old
adults) and degree of chronicity of airway infection. In addition to production by Th17 T cells,
γδ cells, innate lymphoid cells and NK cells, IL-17 can be secreted by neutrophils [9, 11, 23].
Luminal neutrophils might be expected to be a relatively much greater source of IL-17A in old
subjects with stable but established bronchiectasis, while mucosal IL-17A appears to predomi-
nate in childhood bronchiectasis subjects with earlier infection [11]. Consistent with this, we
observed substantially higher neutrophil counts in BALF from our subjects (mean 21 X 106/
mL) than reported in the Tan paper (from Figure 5(C), approx. 150/mL)[11]. Furthermore,
BALF IL-17A levels correlated significantly with BALF neutrophils but not with gene expres-
sion of IL-17A in endobronchial biopsies. Compartmentalization of IL-17A production (lumi-
nal vs. epithelial) in these subjects with established bronchiectasis also explains the apparent
discrepancy between elevated protein levels of IL-17A in BALF but not gene expression
in biopsies.
Prominent neutrophilia is part of the intense cellular infiltration of bronchial mucosa that
has been shown in adult bronchiectasis [21], and neutrophilic inflammation is characteristic of
acute Th17 pathway activation in the lungs [24]. Interestingly however, an IL-17-overexpres-
sing murine model assessed from 5 months showed significant lung inflammation character-
ised by increases in lung macrophage and lymphocyte, but not neutrophil, infiltration [25].
IL-17A release in response to acute infection is predominantly from innate immune cells rather
than Th17 cells [23] and neutrophils were shown to be the main cellular source of IL-17 in a
murine model of inhalational anthrax [26]. Hence, we speculate that neutrophils are the prima-
ry source of airway IL-17A in the chronic airway inflammation characterizing adult non-
CF bronchiectasis.
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Our results suggest relatively greater importance of the neutrophil-related mediators IL-8
and IL-1α, than IL-17A, in adult non-CF bronchiectasis airway mucosal pathophysiology.
Both IL-8 and IL1α, but not IL-17A, correlated with cough symptoms and quality of life mea-
sures. Furthermore, while there were no significant differences in BALF IL-17A levels between
subjects according to important clinical markers, IL-8 levels were significantly increased in
those with the presence of any potentially pathogenic microorganism and also P. aeruginosa in-
fection specifically. Interestingly, those withH. influenzae had levels of IL-1α that were signifi-
cantly higher than those with P. aeruginosa. The demonstration in sputum of significantly
higher levels of neutrophilic inflammatory mediators in subjects with P. aeruginosa infection
has recently been described in a large study [6]. However, we are unaware of any data suggest-
ing either decreased IL-1α levels in subjects with P. aeruginosa (compared to H. influenzae) in-
fection or the possibility of a divergence in the specific inflammatory response according to
specific microbiology. This divergent inflammatory activation might explain the significantly
higher rates of pulmonary exacerbation seen in subjects with P. aeruginosa than H. influenzae
in the BLESS study [13,27,28]. For example, perhaps P. aeruginosaminimizes epithelial IL-1α
(an intracellular cytokine mainly released following cell necrosis) activation and release in
order to evade mucosal immune systems, analogous to its ability to inhibit macrophage IL-1β
production via components of its Type 3 secretory system [29]. It must be recognised that
some of these analyses (based upon concomitant sputum bacterial infection status) were post-
hoc, performed when our initial analysis suggested the possibility of such a relationship accord-
ing to BALF infection status. Further investigation of the specific inflammatory responses of
bronchiectasis model systems to different microbial communities will be informative in
this regard.
There is significant airway luminal activation of the Th-17 pathway in established, adult
non-CF bronchiectasis. However, our results suggest relatively greater importance of non-anti-
gen-specific innate neutrophil-dominated inflammation in the airway pathophysiology of this
condition. We speculate that specific activation of the Th17 pathway is less important in the
longstanding, chronic infection and inflammation that characterises adult bronchiectasis once
neutrophilic inflammation has become established.
Supporting Information
S1 Supporting Information. Data Supplement.
(DOCX)
Acknowledgments
We thank the patients for their enthusiastic involvement in this study and Ms Thu Tran for
her help in sample processing.
Author Contributions
Conceived and designed the experiments: DJS MAM ACHC. Performed the experiments: DJS
MAM ACHCMLM RL GBR LB SZH SDB. Analyzed the data: DJS MAM ACHCMLM RL
GBR LB SZH SDB. Contributed reagents/materials/analysis tools: DJS MAM ACHCMLM RL
GBR LB SZH SDB. Wrote the paper: DJS ACHC. Reviewed and revised: DJS MAM ACHC
MLM RL GBR LB SZH SDB.
Th17 Pathway Activation in Non-CF Bronchiectasis
PLOS ONE | DOI:10.1371/journal.pone.0119325 March 30, 2015 11 / 13
References
1. Tsang KW, Bilton D. Clinical challenges in managing bronchiectasis. Respirology 2009; 14:637–50.
doi: 10.1111/j.1440-1843.2009.01569.x PMID: 19659645
2. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin
Pulm Med 2005; 12:205–9.
3. O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterization of patients di-
agnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55:635–42. PMID:
10899238
4. Martinez-Garcia MA, de la Rosa Carrillo D, Soler-Cataluna JJ, Donat-Sanz Y, Serra PC, Lerma MA,
et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmo-
nary disease. Am J Respir Crit Care Med 2013; 187:823–31. doi: 10.1164/rccm.201208-1518OC
PMID: 23392438
5. Angrill J, Agusti C, De Celis R, Filella X, Rañó A, ElenaM, et al. Bronchial inflammation and colonisation
in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164:1628–32. PMID:
11719301
6. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic
treatment reduces airway and systemic inflammation in non-CF bronchiectasis. Am J Respir Crit Care
Med 2012; 186:657–665. doi: 10.1164/rccm.201203-0487OC PMID: 22744718
7. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al. Clinical mea-
sures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax
2013; 68:731–7. doi: 10.1136/thoraxjnl-2012-203105 PMID: 23564400
8. Cole PJ. Inflammation: a two-edged sword—the model of bronchiectasis. Eur J Respir Dis Suppl 1986;
147:6–15. PMID: 3533593
9. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;
361:888–98. doi: 10.1056/NEJMra0707449 PMID: 19710487
10. Zheng L, LamWK, Tipoe GL, Shum IH, Yan C, Leung R, et al. Overexpression of matrix metalloprotei-
nase-8 and -9 in bronchiectatic airways in vivo. Eur Respir J 2002; 20:170–6. PMID: 12166566
11. Tan HL, Regamey N, Brown S, Bush A, Lloyd CM, Davies JC. The Th17 pathway in cystic fibrosis lung
disease. Am J Respir Crit Care Med 2011; 184;252–258. doi: 10.1164/rccm.201102-0236OC PMID:
21474644
12. Tiringer K, Treis A, Fucik P, Gona M, Gruber S, Renner S, et al. A Th17- and Th2-skewed cytokine pro-
file in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am
J Respir Crit Care Med 2013; 187:621–629. doi: 10.1164/rccm.201206-1150OC PMID: 23306544
13. Fouka E, Lamprianidou E, Arvanitidis K, Filidou E, Kolios G, Miltiades P, et al. Low-dose clarithromycin
therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients. Lung 2014; 192: 849–
55. doi: 10.1007/s00408-014-9619-0 PMID: 25016929
14. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose
erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the
BLESS randomized controlled trial. JAMA 2013; 309:1260–1267. doi: 10.1001/jama.2013.2290 PMID:
23532242
15. Serisier DJ, Martin M. Long-term, low-dose erythromycin in subjects with frequent exacerbations.
Respir Med 2011; 105:946–9. doi: 10.1016/j.rmed.2011.01.009 PMID: 21367595
16. Decraene A, Willems-Widyastuti A, Kasran A, Boeck K, Bullens DM, Dupont LJ. Elevated expression of
both mRNA and protein levels of IL-17a in sputum of stable cystic fibrosis patients. Respir Res 2010;
11:177. doi: 10.1186/1465-9921-11-177 PMID: 21143945
17. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, et al. Role of IL-17A, IL-17F, and the
IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor
in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005;
175;404–412. PMID: 15972674
18. Brodlie M, Corris PA, Lordan J, Ward C. Interleukin-17 and cystic fibrosis lung disease. Am J Respir
Crit Care Med 2012; 185:108–9. PMID: 22210793
19. Tan HL, Davies J, Brown S, Bush A, Lloyd CM, Davies JC. Response to Brodlie et al. Am J Respir Crit
Care Med 2012; 185:109–10.
20. Vanaudenaerde BM, Verleden SE, Vos R, De Vleeschauwer SI, Willems-Widyastuti A, Geenens R,
et al. Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders.
Am J Respir Crit Care Med 2011; 183:977–86. doi: 10.1164/rccm.201007-1196PP PMID: 21097694
Th17 Pathway Activation in Non-CF Bronchiectasis
PLOS ONE | DOI:10.1371/journal.pone.0119325 March 30, 2015 12 / 13
21. Gaga M, Bentley AM, Humbert M, Barkans J, O'Brien F, Wathen CG, et al. Increases in CD4+ T lym-
phocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bron-
chiectasis. Thorax 1998; 53:685–691. PMID: 9828857
22. Zheng L, Shum H, Tipoe GL, Leung R, LamWK, Ooi GC, et al. Macrophages, neutrophils and tumour
necrosis factor-alpha expression in bronchiectatic airways in vivo. Respir Med 2001; 95:792–798.
PMID: 11601743
23. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol
2010; 10: 479–89. doi: 10.1038/nri2800 PMID: 20559326
24. Tsai H-C, Velichko S, Hung L-Y, Wu R. IL-17a and Th17 cells in lung inflammation: an update on the
role of Th17 cell differentiation and IL-17R signaling in host defense against infection. Clin Dev Immunol
2013; 2013:267971. doi: 10.1155/2013/267971 PMID: 23956759
25. Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, et al. Regulation of inflammatory responses
by IL-17F. J Exp Med 2008; 205:1063–75. doi: 10.1084/jem.20071978 PMID: 18411338
26. Garraud K, Cleret A, Mathieu J, Fiole D, Gauthier Y, Quesnel-Hellmann A. Differential role of the inter-
leukin-17 axis and neutrophils in resolution of inhalational anthrax. Infect Immun 2012; 80: 131–42.
doi: 10.1128/IAI.05988-11 PMID: 22025514
27. Rogers GB, Zain MMH, Bruce KD, Burr LD, Chen AC, Rivett DW, et al. A novel microbiota stratification
system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014; 11:496–503. doi:
10.1513/AnnalsATS.201310-335OC PMID: 24592925
28. Rogers GB, Bruce KD, Burr L, Martin M, Serisier DJ. The effect of long-termmacrolide treatment on re-
spiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised,
double-blind, placebo-controlled BLESS trial. Lancet Respir Med 2014; 2: 988–96. doi: 10.1016/
S2213-2600(14)70213-9 PMID: 25458200
29. Sutterwala FS, Mijares LA, Li Q, Ogura Y, Kazmierczak BI, Flavell RA. Immune recognition of Pseudo-
monas aeruginosamediated by the IPAF/ NRLC4 inflammasome. J Exp Med 2007; 204: 2235–45.
Th17 Pathway Activation in Non-CF Bronchiectasis
PLOS ONE | DOI:10.1371/journal.pone.0119325 March 30, 2015 13 / 13
